Publications by authors named "Maryam Miladi"
Article Synopsis
- Sezary syndrome (SS) used to have very few treatment options and not a good outlook for patients, but new therapies are helping a lot.
- In a study of 178 patients treated from 2012 to 2020, more advanced treatments led to much better survival rates: about 56% of patients lived at least 5 years.
- Patients who had a special treatment called allogeneic stem-cell transplantation (AlloSCT) had even better chances to survive, with around 91% living for 5 years, but those who couldn't get that treatment still faced challenges.
Despite increasing availability of therapies, patients with Sezary syndrome (SS) commonly endure multi-line treatment journeys, mostly with partial responses of short duration. Measuring clinical benefit is challenging; time-to-next-treatment (TTNT) provides a robust, objective measurement of efficacy. This international observational study examines patterns of clinical care and therapeutic benefit as measured by TTNT.
View Article and Find Full Text PDF